Are Medicines on TrumpRx Seeing a Boost in Prescriptions? The Data Suggests the Answer Is (Mostly) ‘No’
And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in
Mar 6, 2026
Subscribe to Cost Curve Apex to read the rest.
Upgrade to Apex to get access to this post and other subscriber-only content.
Upgrade